The Indian Pharmaceutical Market Outlook To 2014: Market trends, key players, forecast

The Indian Pharmaceutical Market Outlook To 2014: Market trends, key players, forecast
Executive summary 10

Overview of India 10

The Indian healthcare system 11

The pharmaceutical industry in India 12

Key players in the Indian pharmaceutical market 13

Indian pharmaceutical market SWOT analysis 14

Chapter 1 Scope and methodology 16

Scope 16

Methodology 16

Scope of IMS data 17

Chapter 2 Overview of India 20

Summary 20

Introduction 21

Overview of Indian history 21

The government 21

A burgeoning economy 22

Key economic parameters 23

An imprint of the global slowdown 24

Population profile and demographic trends 26

Disease burden 27

Vector-borne diseases 31

Chapter 3 The Indian healthcare system 34

Summary 34

Introduction 35

Healthcare system 37

The rural healthcare system 38

The urban healthcare system 39

Specialist and emergency medical care 40

The regulatory set-up 41

Intellectual property rights 41

Effect of IPR regime on innovation 42

Financing healthcare 43

Inefficiencies fueled by underutilization of funds 45

Pricing and reimbursement 46

Private health insurance 47

Private healthcare 49

A range of private healthcare services 50

Public-private partnerships 50

Alternative medicine: AYUSH 51

Ayurveda 51

Yoga 52

Naturopathy 52

Unani 52

Siddha 53

Homoeopathy 53

Chapter 4 The pharmaceutical market in India 56

Summary 56

Introduction 57

Key market trends, events and issues 59

Therapy area analysis 64

Therapy area sales forecast 74

Leading brands 75

Leading brands sales forecast 79

Over-the-counter medication 80

The Indian generics advantage 80

Chapter 5 Key players in the Indian pharmaceutical market 84

Summary 84

Introduction 85

Leading players of the Indian pharmaceutical market 86

Detailed analysis of the Indian pharmaceutical market players 87

Cipla 87

Overview 87

Sales focus by leading drug classes 88

Sales focus by leading brands 91

New product launches 92

SWOT analysis 94

Strengths 94

Weaknesses 95

Opportunities 96

Threats 96

Ranbaxy 97

Overview 97

Sales focus by leading drug classes 97

Sales focus by leading brands 99

R&D pipeline analysis 101

SWOT analysis 103

Strengths 103

Weaknesses 104

Opportunities 105

Threats 106

GlaxoSmithKline (India) 106

Overview 106

Sales focus by leading drug classes 107

Sales focus by leading brands 108

R&D pipeline analysis 111

SWOT analysis 112

Strengths 112

Weaknesses 113

Opportunities 113

Threats 115

Piramal Healthcare 115

Overview 115

Sales focus by leading drug classes 115

Sales focus by leading brands 117

R&D pipeline analysis 119

SWOT analysis 120

Strengths 120

Weaknesses 122

Opportunities 122

Threats 123

Zydus Cadila 123

Overview 123

Sales focus by leading drug classes 124

Sales focus by leading brands 125

R&D pipeline analysis 126

SWOT analysis 127

Strengths 127

Weaknesses 128

Opportunities 128

Threats 129

A snapshot of other key market players 129

Sun Pharma 129

Lupin 130

Alkem 131

Sanofi-Aventis 132

Mankind Pharma 133

Leading players in the Indian pharmaceutical market: sales forecast 134

Chapter 6 Appendix 136

IMS data 136

Anatomical Therapeutic Classification (ATC) 136

A: Alimentary tract and metabolism 136

B: Blood and blood-forming organs 136

C: Cardiovascular system 136

D: Dermatologicals 137

G: Genito-urinary system and sex hormones 137

H: Systemic hormonal preparations 137

J: General anti-infectives systemic 137

L: Antineoplastic and immunomodulating agents 137

M: Musculo-skeletal system 137

N: Nervous system 138

R: Respiratory system 138

S: Sensory organs 138

T: Diagnostic agents 138

V: Various 138

Glossary 139

Index 141

List of Figures

Figure 1.1: Indian pharmaceutical market SWOT analysis 14

Figure 2.2: Real GDP growth rate at factor cost across different quarters of the fiscal years 2008

and 2009 (%) 24

Figure 2.3: Comparative position ($bn) of India among the top service exporters globally, 2007 25

Figure 2.4: Deaths by cause for non-communicable diseases in India, 2005 28

Figure 3.5: Total expenditure on health per capita ($) in seven emerging pharmaceutical markets,

2006 36

Figure 3.6: Rural healthcare network in India 39

Figure 3.7: Public spending on healthcare (% GDP) in India, 1950-2006 44

Figure 4.8: Comparative position of India among the different global markets, 2008 58

Figure 4.9: Top 10 drug classes of the alimentary tract and metabolism therapy area ($m), 2008 66

Figure 4.10: Top 10 drug classes of the anti-infective therapy area ($m), 2008 68

Figure 4.11: Top 10 drug classes of the cardiovascular system therapy area, ($m) 2008 69

Figure 4.12: Top 10 drug classes of the respiratory system therapy area ($m), 2008 70

Figure 4.13: Top 10 drug classes of the nervous system therapy area ($m), 2008 72

Figure 4.14: Therapy area sales growth trend, 2004-08 73

Figure 5.15: Market share of leading players in the Indian pharmaceutical market (%), 2008 86

Figure 5.16: Cipla's Indian market sales by therapy area ($m), 2008 89

Figure 5.17: Cipla's SWOT analysis 94

Figure 5.18: Ranbaxy's Indian market sales by therapy area ($m), 2008 98

Figure 5.19: Ranbaxy's SWOT analysis 103

Figure 5.20: GSK's Indian market sales by therapy area ($m), 2008 107

Figure 5.21: GSK (India) SWOT analysis 112

Figure 5.22: Piramal Healthcare's Indian market sales by therapy area ($m), 2008 116

Figure 5.23: Piramal Healthcare's SWOT analysis 120

Figure 5.24: Zydus Cadila's Indian market sales by therapy area ($m), 2008 124

Figure 5.25: Zydus Cadila's SWOT analysis 127

List of Tables

Table 2.1: Political snapshot of India 22

Table 2.2: Economic snapshot of India 23

Table 2.3: Demographic snapshot of India 26

Table 2.4: Ten leading causes of death (%) in India, 2002 27

Table 2.5: Forecast epidemiology of major diseases in India, 2008-14 29

Table 2.6: Vector-borne diseases in India 31

Table 4.7: Indian pharmaceutical market by therapy area sales, 2008 65

Table 4.8: Indian pharmaceutical market therapy area sales forecast ($m), 74

Table 4.9: Indian pharmaceutical market by leading brands, 2008 75

Table 4.10: Top 10 brands of the Indian pharmaceutical market, sales forecast 2008-14 79

Table 5.11: Leading players of the Indian pharmaceutical market by sales, 2008 87

Table 5.12: Cipla's leading brands in the Indian market (($m), 2008 91

Table 5.13: Leading recently launched products of Cipla in the Indian market 93

Table 5.14: Leading brands of Daiichi-Ranbaxy in the Indian market ($m), 2008 100

Table 5.15: Leading pipeline compounds of Ranbaxy in the Indian market 102

Table 5.16: Leading brands of GSK in the Indian market, 2008 109

Table 5.17: Key patented products of GSK launched in India 114

Table 5.18: Leading brands of Piramal Healthcare in the Indian market, 2008 118

Table 5.19: Piramal Healthcare's key acquisitions 121

Table 5.20: Piramal Healthcare's key alliances and licensing agreements 122

Table 5.21: Leading brands of Zydus Cadila in the Indian market, 2008 125

Table 5.22: Key pipeline drugs for Zydus Cadila 126

Table 5.23: Leading players in the Indian pharmaceutical market, sales forecast 2008-14 134